#BioLOGIC - Twitter Hashtag

5 days ago

Novel Two-#Prong #Biologic Shows Promise in #Asthma — Phase II study finds benefits with multi-targeting of inflammatory pathways. https://t.co/XRELI48gUc

Aller_MD's tweet photo. Novel Two-#Prong #Biologic Shows Promise in #Asthma — Phase II study finds benefits with multi-targeting of inflammatory pathways. https://t.co/XRELI48gUc https://t.co/DQR7wgAMs9

0

4

3

0

194

Juan C Ivancevich MD @Aller_MD

6 days ago

#Pediatric #Atopic #Dermatitis: #Biologic Revolution Continues as Therapeutic Targets Expand. https://t.co/0Ll37GJ7KW

0

1

3

0

129

Interasma @Interasma

14 days ago

Comparative effectiveness of #biologic #therapies for preventing #asthma #exacerbations in severe asthma: a systematic review and network meta-analysis. Open Access. https://t.co/AGaGdAoSYn

Interasma's tweet photo. Comparative effectiveness of #biologic #therapies for preventing #asthma #exacerbations in severe asthma: a systematic review and network meta-analysis. Open Access. https://t.co/AGaGdAoSYn https://t.co/AUf29sgCrt

1

2

3

0

157

Juan C Ivancevich MD @Aller_MD

20 days ago

Severe #asthma remains active in most despite widespread #biologic #treatment: although 79% of the patients were treated with biologic therapies, many still showed signs of active disease. https://t.co/5Hi152mMw9

Aller_MD's tweet photo. Severe #asthma remains active in most despite widespread #biologic #treatment: although 79% of the patients were treated with biologic therapies, many still showed signs of active disease. https://t.co/5Hi152mMw9 https://t.co/uLKXxIQLfd

0

4

6

1

218

World Allergy Organization @worldallergy

about 1 month ago

#WAOJournal: Prevalence and #cost implications of broadening #asthma #biologic #eligibility criteria. Open Access. https://t.co/Tc4KFHXsyM

worldallergy's tweet photo. #WAOJournal: Prevalence and #cost implications of broadening #asthma #biologic #eligibility criteria. Open Access. https://t.co/Tc4KFHXsyM https://t.co/lEYpXcG7Y3

0

6

5

0

342

Origo M

@origo_biologic

about 2 months ago

Introduction to bioLogic™ - A novel & practical approach to human behavior, mental health & healing. #psychology #metabolichealth #bioLogic

0

4

0

358

Antibodies MDPI @Antibodies_MDPI

2 months ago

Glad to share this paper @MediPharma_MDPI "pIgR Stem Zone-Targeted #Nanobodies as Apical-to-Basolateral Carriers for Inhaled #Biologic #Delivery Across Mucosal Barriers" https://t.co/GiWp6S06kk

Antibodies_MDPI's tweet photo. Glad to share this paper @MediPharma_MDPI

"pIgR Stem Zone-Targeted #Nanobodies as Apical-to-Basolateral Carriers for Inhaled #Biologic #Delivery Across Mucosal Barriers"

https://t.co/GiWp6S06kk https://t.co/ZdXxqwN7aG

0

3

1

0

281

Interasma @Interasma

3 months ago

#Depemokimab: toward biannual #biologic therapy for severe #eosinophilic #asthma. Open Access. https://t.co/NJiaNvqdaB

0

6

3

0

216

NWORobotics @NWORobotics

3 months ago

#CISS #SPINGATE #BIOLOGIC · V1: Chirality-Induced Spin Selectivity (CISS) meets biological logic. The V1 gateway utilizes spin-polarized electron transfer to gate biochemical reactions with extreme spatial specificity. https://t.co/zCqSPGLWLh #CISS #MolecularElectronics #BioLogic

1

5

4

0

104

Interasma @Interasma

4 months ago

A self-controlled case series to evaluate the effects of clinical trial eligibility #criteria on #biologic-associated #reductions in severe #asthma #exacerbations: an analysis of the CHRONICLE Study. https://t.co/JiDlBiL6XW

Interasma's tweet photo. A self-controlled case series to evaluate the effects of clinical trial eligibility #criteria on #biologic-associated #reductions in severe #asthma #exacerbations: an analysis of the CHRONICLE Study. https://t.co/JiDlBiL6XW https://t.co/pifgtsFfc8

0

3

1

147

Juan C Ivancevich MD @Aller_MD

4 months ago

Initiation of #biologic treatment for #asthma is low despite availability, and #adherence is low as well despite its association with good outcomes, according to data presented at the #American #Thoracic #Society #Annual #Meeting. https://t.co/5xZpSVDWpF

Aller_MD's tweet photo. Initiation of #biologic treatment for #asthma is low despite availability, and #adherence is low as well despite its association with good outcomes, according to data presented at the #American #Thoracic #Society #Annual #Meeting.
https://t.co/5xZpSVDWpF https://t.co/Tm0Ox5JE6k

0

5

3

0

152

A Chronic Voice @AChVoice

4 months ago

“[My #doctor] predicted in 2022 that I’d be a patient who needs #biologic swapping therapy every 6 months to a year and he has been right. This is why I’ve been through so many #medications.”: https://t.co/XaXY1pSwg7 by @globetrotteri #ChronicIllness #AutoimmuneDisease #AxSPA

1

5

2

0

77

COPD Foundation @COPDFoundation

5 months ago

Now available on demand on @medliveofficial This expert-led #CME program explores type 2 inflammation and eosinophils in #COPD and offers practical, guideline-based strategies to individualize care, including the use of emerging #biologic therapies. ▶️https://t.co/52h1XujDzZ

COPDFoundation's tweet photo. Now available on demand on @medliveofficial

This expert-led #CME program explores type 2 inflammation and eosinophils in #COPD and offers practical, guideline-based strategies to individualize care, including the use of emerging #biologic therapies.

▶️https://t.co/52h1XujDzZ https://t.co/TM7NCdU0d8

1

4

3

0

275

Interasma @Interasma

5 months ago

Infographic: Beyond the Clinic: Are We Underestimating #Asthma #Biologic #Adherence? https://t.co/Xrj15kgUVo

0

5

0

290

Juan C Ivancevich MD @Aller_MD

6 months ago

Going from a medium-dose #inhaled #corticosteroid to a #biologic for #asthma led to significant decreases in #exacerbations, according to a poster presented at the American Academy of #Allergy, Asthma & #Immunology Annual Meeting. https://t.co/5e6d2H1PkN

Aller_MD's tweet photo. Going from a medium-dose #inhaled #corticosteroid to a #biologic for #asthma led to significant decreases in #exacerbations, according to a poster presented at the American Academy of #Allergy, Asthma & #Immunology Annual Meeting. https://t.co/5e6d2H1PkN https://t.co/AVSs77bCBi

0

4

1

140

A Chronic Voice @AChVoice

6 months ago

"Rheuminococcus gnavus #bacteria may be associated with #lupus and #LupusNephritis. Treating R. gnavus could limit the need for #biologic or DMARD therapy in some patients with lupus": https://t.co/Shx5GA172e via @GoHealio #MedicalResearch #GutMicrobe #autoimmune #ChronicIllness

0

6

1

93

World Allergy Organization @worldallergy

6 months ago

#WAOJournal: Indication for #biologic #treatment in a real-world cohort of #chronic #rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR). Open Access. https://t.co/NSQagMdG9U

worldallergy's tweet photo. #WAOJournal: Indication for #biologic #treatment in a real-world cohort of #chronic #rhinosinusitis patients according to international recommendations: Evidence from the European CRS outcome registry (CHRINOSOR). Open Access. https://t.co/NSQagMdG9U https://t.co/7mHnajzZ3r

0

8

5

1

385

Juan C Ivancevich MD @Aller_MD

6 months ago

‘There’s still something we are missing’ - #biologics #underused in #multinational #survey: less than 15% of adults with #uncontrolled #asthma eligible for #biologic #therapy reported current biologic use, according to survey data. https://t.co/nrQgLsUFDy

Aller_MD's tweet photo. ‘There’s still something we are missing’ - #biologics #underused in #multinational #survey: less than 15% of adults with #uncontrolled #asthma eligible for #biologic #therapy reported current biologic use, according to survey data. https://t.co/nrQgLsUFDy https://t.co/JKYW4nlu5r

0

7

3

0

101

World Allergy Organization @worldallergy

6 months ago

Two new #WAO committee papers published: “What is new on the horizon for the #biologic therapies world: New treatments at the starting blocks” and "World Allergy Organization survey on the diagnosis and management trends of #perioperative #anaphylaxis". https://t.co/2TADGV9Ssp

worldallergy's tweet photo. Two new #WAO committee papers published: “What is new on the horizon for the #biologic therapies world: New treatments at the starting blocks” and "World Allergy Organization survey on the diagnosis and management trends of #perioperative #anaphylaxis".
https://t.co/2TADGV9Ssp https://t.co/boBgZdczdb

0

4

0

265

Alberto Giraldo

@alb_giraldo

6 months ago

#Women with #spondyloarthritis (SpA) show markedly shorter persistence on first and second #biologic #DMARDs (bDMARDs) despite similar initiation timing, as demonstrated by real-world data from Spanish REGISPONSER/REGISPON-3 registry: ◦ Study population: 411 SpA patients (271 males, 140 females) followed for 17 years (REGISPONSER → REGISPON-3). ◦ bDMARD initiation: No significant sex difference in time to first bDMARD (from symptoms or diagnosis). ◦ Males showed significantly longer persistence (retention) on bDMARD therapy compared to females: - First bDMARD: males 88 months vs females 48 months (p = 0.004) - Second bDMARD: males 260 months vs females 133 months (p = 0.0007) ◦ Multivariable analyses (Cox proportional hazards models) revealed sex-specific predictors of bDMARD initiation. ◦ The main reason for discontinuation was inefficacy in both sexes, but adverse events were reported more frequently as a reason for stopping treatment in females. These findings indicate that while the timing of starting bDMARDs is similar between males and females with SpA, women demonstrate significantly shorter persistence on biological treatments over the long-term follow-up. *Moldovan DMM, Ladehesa-Pineda L, Puche-Larrubia MÁ et al. Sex-based differences in bDMARD initiation and persistence in spondyloarthritis: a 17-year follow-up study from the REGISPON-3 registry. Rheumatology (Oxford). Published online March 21, 2026. 🔗https://t.co/P2UVjRv2pP

alb_giraldo's tweet photo. #Women with #spondyloarthritis (SpA) show markedly shorter persistence on first and second #biologic #DMARDs (bDMARDs) despite similar initiation timing, as demonstrated by real-world data from Spanish REGISPONSER/REGISPON-3 registry:

◦ Study population: 411 SpA patients (271 males, 140 females) followed for 17 years (REGISPONSER → REGISPON-3).

◦ bDMARD initiation: No significant sex difference in time to first bDMARD (from symptoms or diagnosis).

◦ Males showed significantly longer persistence (retention) on bDMARD therapy compared to females:
- First bDMARD: males 88 months vs females 48 months (p = 0.004)
- Second bDMARD: males 260 months vs females 133 months (p = 0.0007)

◦ Multivariable analyses (Cox proportional hazards models) revealed sex-specific predictors of bDMARD initiation.

◦ The main reason for discontinuation was inefficacy in both sexes, but adverse events were reported more frequently as a reason for stopping treatment in females.

These findings indicate that while the timing of starting bDMARDs is similar between males and females with SpA, women demonstrate significantly shorter persistence on biological treatments over the long-term follow-up.

*Moldovan DMM, Ladehesa-Pineda L, Puche-Larrubia MÁ et al. Sex-based differences in bDMARD initiation and persistence in spondyloarthritis: a 17-year follow-up study from the REGISPON-3 registry. Rheumatology (Oxford). Published online March 21, 2026.
🔗https://t.co/P2UVjRv2pP

1

14

6

2

644

Top Tweets for #BioLOGIC

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users